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Background: Oral potentially malignant disorders (OPMDs) comprise a range of clinical-pathological alterations 
that are frequently characterized as architectural and cytological derangements upon histological analysis. Epithe-
lial-mesenchymal transition (EMT) has been proposed as a critical mechanism for the acquisition of the malignant 
phenotype in neoplastic epithelial processes. This study aims to systematically review the current findings on the im-
munohistochemical expression of epithelial-mesenchymal transition markers in oral potentially malignant disorders 
and to evaluate their possible application as biomarkers associated with the progression of oral epithelial dysplasias.
Material and Methods: A systematic search was performed in the following databases: PubMed, EMBASE, Chi-
nese BioMedical Literature Database, and Cochrane Library. Articles that evaluated the relationship between the 
expression of EMT markers and the degree of oral epithelial dysplasia were selected for the systematic review. 
The quality of each eligible study was evaluated by independent reviewers that used operationalized prognostic 
biomarker reporting guidelines (REMARK).
Results: Seventeen articles met all inclusion criteria and were selected. The EMT markers analyzed exhibited an 
important association with the prognosis of the cases evaluated. The results showed a progressive increase in the 
expression of nuclear transcription factors and markers of mesenchymal differentiation, as well as negative regu-
lation of epithelial and cell adhesion markers, according to the stage of oral epithelial dysplasia.
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independent variables were clinicopathological param-
eters and oral epithelial dysplasia grading. The Report-
ing Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines were followed (13).
- Search strategy
The research question was “Are epithelial-mesenchy-
mal transition biomarkers analyzed by immunohisto-
chemistry potential predictors/prognostic factors for 
oral epithelial dysplasia?” and a keyword search was 
performed. 
To identify all primary research articles that evalu-
ated EMT biomarkers in oral epithelial dysplasia, we 
searched the MEDLINE/PubMed (1966 to January 
2019), EMBASE (1980 to January 2019), Cochrane 
Collaboration Library (2009 to January 2019), and Chi-
nese BioMedical Literature Databases (1978 to January 
2019). The search strategy was based on combinations 
of the following keywords: (“Oral epithelial dyspla-
sia” [MeSH] AND “Immunohistochemistry” [MeSH] 
AND “biomarkers of epithelial-mesenchymal transi-
tion” [MeSH] AND “clinicopathological parameters” 
[MeSH] AND “outcome” [MeSH]) AND (risk ratio [Ti-
tle/Abstract] OR relative risk [Title/Abstract] OR odds 
ratio [Title/Abstract] OR risk [Title/ Abstract]) AND 
(“humans”[MeSH Terms]). A manual search of articles 
was also performed using the references within studies 
with inclusion potential in the systematic review.
- Selection criteria
Articles were included based on a previously published 
protocol (14,15). Studies that assessed the relationship 
between the immunohistochemical expression of EMT 
markers and histopathological grading of cases diag-
nosed with oral epithelial dysplasia were selected. The 
search was carried out without time and language re-
strictions. The PICOS (population, intervention, com-
parison, outcome, study design) format was used to 
construct the research question using the following in-
clusion criteria: (I) Population: patients diagnosed with 
oral epithelial dysplasia; (II) Intervention: immunohis-
tochemical analysis of EMT markers; (III) Outcome: 
risk of progression from oral epithelial dysplasia; (IV) 
Study Design: observational studies in humans.
We limited selection to human studies on oral epithelial 
dysplasia defined based on standardized histological as-
sessment as outlined by the WHO (16). We included all 
studies that reported data for progressing and non-pro-
gressing oral epithelial dysplasias. Both prospective and 
retrospective studies were included. Progressing lesions 
Introduction
Oral potentially malignant disorders (OPMDs) com-
prise a range of clinical-pathological alterations that are 
frequently characterized as architectural and cytologi-
cal derangements upon histological analysis (1-3). OP-
MDs exhibit an increased risk of malignant transforma-
tion. A recent meta-analysis estimated an overall risk 
of malignant transformation of 10.5% for oral epithelial 
dysplasia (4).
The potential of malignant transformation is believed 
to be related to the degree of epithelial dysplasia ob-
served (2-4). Several studies have been conducted to 
identify possible markers that can trigger the develop-
ment of OPMDs as well as predict their progression 
(2,5,6). The epithelial-mesenchymal transition (EMT) 
is a mechanism frequently dysregulated in cancer (5-
10,12). However, studies evaluating the role of EMT in 
the development/progression of dysplastic processes in 
oral epithelium are scarce.
The EMT, which is an essential event during embryo-
genesis, is a biological process in which epithelial cells 
lose their characteristics and shift to a mesenchymal 
cell-like phenotype. This process has been proposed 
as a critical mechanism for the acquisition of the ma-
lignant phenotype in neoplastic epithelial processes 
(5,8,9,12). EMT is mediated by nuclear transcription 
factors and can orchestrate intracellular alterations such 
as the negative regulation of epithelial markers, as well 
as the positive regulation of some mesenchymal mark-
ers (7,8,10).
A variety of biomarkers are known to be associated with 
EMT. These biomarkers can be divided into five groups 
according to their characteristics/functions: 1. cell sur-
face markers; 2. cytoskeletal markers; 3. extracellular 
proteins; 4. transcription factors; 5. epigenetic markers 
and microRNAs.8 Recent studies indicate that impor-
tant EMT markers may be involved in the malignant 
transformation of cases diagnosed as OPMD (5,11,12).
In this study, a systematic review was conducted to clar-
ify the prognostic value of EMT biomarkers in OPMDs. 
The review includes publications that evaluated the im-
munodetection of EMT markers and their possible use as 
prognostic factors/predictors in oral epithelial dysplasia.
Material and Methods
We performed a systematic review to conduct this in-
vestigation. The dependent variables were biomarkers 
of EMT available by immunohistochemistry and the 
Conclusions: The dysregulation of expression of important EMT components in oral dysplastic epithelium is a po-
tential prognostic marker in OPMDs.
Key words: Oral potentially malignant disorder, oral epithelial dysplasia, epithelial-mesenchymal transition, biomark-
er, prognosis.
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were defined as those dysplasias that developed cancer 
at the same site as the initial biopsy when followed over 
time. Biomarkers of EMT were defined according to the 
study by Zeisberg & Neilson (8).
In the screening of titles or abstracts, citations were re-
tained if they were original studies, except for reviews 
or meeting reports, that explored associations between 
the immunoexpression of the EMT markers, clinico-
pathological characteristics, and outcome/progression 
of the oral epithelial dysplasia cases analyzed. The 
articles were selected independently by two reviewers 
(EFM and JCP). Any disagreement was resolved by 
consensus.
In the final full-text screening, studies were included if 
they met the following criteria: (I) designed as a pro-
spective or retrospective cohort study; (II) oral epitheli-
al dysplasia was diagnosed and histopathological grad-
ing was performed by pathological examination; (III) 
data about the association between the EMT biomarker 
evaluated and histopathological grading were reported. 
When studies were based on overlapping data, the more 
comprehensive set was selected.
- Data extraction and analysis
Quality assessment was performed in duplicate for each 
eligible study by three independent reviewers using the 
Newcastle operationalized prognostic biomarker re-
porting guidelines (REMARK) (15). Any disagreement 
was resolved by consensus. Studies receiving a score of 
less than 6 were not included in the systematic review. 
Three reviewers (EFM, JASL, RPM) independently ex-
tracted the data from the selected articles.
- Risk of bias in individual studies Methodologically, 
the authors appraised all of the included studies accord-
ing to a checklist based in Meta -Analysis of Statistics 
Assessment and Review Instrument (MAStARI) (17). 
Two reviewers (EFM and RPM) answered 9 questions 
for descriptive studies as Y for “yes”, N for “no”, U for 
“unclear” and NA for “not applicable”. After that, the 
risk of bias was categorized as high when the study 
reached up to 49% of a “yes” score, moderate when the 
study reached 50% to 69% of a “yes” score, and low 
when the study reached more than 70% of a “yes” score. 
Disagreements were solved by discussion between the 
four authors (EFM, RPM, JCP, JASL).
Results
- Study selection and characteristics
The database searches and manual search developed in 
this systematic review retrieved 378 studies. After read-
ing the titles and abstracts, 54 studies were considered 
potentially eligible and their full text was read by three 
reviewers. Seventeen articles met all inclusion criteria 
and were selected for this systematic review (5,18-33). 
Fig. 1 illustrates the flow diagram of the screening and 
selection process of the articles.
The selected articles were observational studies pub-
lished between 2007 and 2018, all of them in English. 
Regarding methodological characteristics, all articles 
included in this systematic review involved 1,178 pa-
tients, with a mean of 69.2 participants per study. Our 
analysis revealed that 743 (63%) of the cases evaluated 
were lesions diagnosed in different stages of epithelial 
dysplasia. Among these cases, 48.7% were graded as 
mild epithelial dysplasia and 51.3% as moderate or se-
vere epithelial dysplasia. The main characteristics and 
findings of the studies are shown in Table 1.
Most of the epithelial dysplasia cases were clinically 
diagnosed as leukoplakia and/or erythroplakia. Anura 
et al. (25) and Sharada et al. (33) also evaluated tis-
sue samples of oral submucosal fibrosis. Twelve stud-
ies included samples of oral squamous cell carcinoma 
(OSCC) for biomarker analysis, totaling 426 cases ana-
lyzed (5,18,21,23,24,26-28,31-33).
Fig. 1: PRISMA flow diagram of screened studies.
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Table 1: Summary of the descriptive characteristics and results of the included studies (n=17).
Author (year) Samples OPMD le-
sion subtype 
(Diagnosis)
Oral Subsite Marker Specimen 
type
Summary of the results
Ishida et al. 
(2007)
Group I (n = 9) - mild ED
Group III (n = 3) - severe ED
Group IV (n = 6) - NOM
Group V (n = 15) - OSCC
Leukoplakia NE β-catenin Tissue (F) Nuclear β-catenin expression 
was significantly different be-
tween dysplasia and normal oral 
epithelium (P < 0.01), as well as 
between oral leukoplakia with 
and without dysplasia (P < 0.01). 
Lo Muzio et al. 
(2009) 
Group I (n = 21) - mild ED
Group II (n = 15) - moderate ED
Group III (n = 13) - severe ED
NE NE β-catenin
γ-catenin
Tissue (F) β- and γ-catenin were different-
ly expressed according to dys-
plasia grade. As the degree of 
dysplasia became more severe, 
it was observed a reduction of 
catenins expression, loss of the 
exclusive membranar expression 
and cytoplasmic delocalization.
Carvalho et al. 
(2010) 
Group I (n = 19) - mild ED
Group II (n = 26) - moderate ED
Group III (n = 3) - severe ED
NE NE Claudin-1 Tissue (F) Alterations in the immunoex-
pression of claudin-1 between 
different grades of EDs suggest 
the involvement of this protein 
in the progression of oral EDs.
Chaw et al. 
(2012) 
Group I (n = 27) - mild ED
Group II (n = 8) - moderate/se-
vere ED
Group III (n = 18) - NOM





Tissue (F) Aberrant expression of β-catenin 
and vimentin may be related to 
malignant transformation.
Inoue et al. 
(2012) 
Group I (n = 49) - mild ED
Group II (n = 19) - moderate ED
Group III (n = 31) - severe ED/CIS









Tissue (F) Immunoreactivity for podo-
planin was detected in 89 
(86.4%) of the potentially ma-
lignant lesions and staining in-
tensity was correlated with the 
degree of epithelial dysplasia 
(P = 0.016). Podoplanin may be 
associated with tumor develop-
ment via the oral dysplasia–car-
cinoma.
Silva et al. 
(2012) 
Group I (n = 10) - mild ED
Group II (n = 10) - moderate ED
Group III (n = 10) - severe ED
Group IV (n = 10) –NOM
Group V (n = 20) - OSCC







Tissue (F) A significant difference in Twist 
and p-Akt immunoexpression 
among NOM, EDs and OSCC 
was observed. In addition, a sig-
nificant positive correlation was 
found between Twist and p-Akt 
expressions. These results sug-
gest that Twist and p-Akt par-
ticipate of the multistep process 
of oral carcinogenesis since its 
early stages.
Rani et al. 
(2013) 
Group I (n = 27) - mild ED
Group II (n = 8) - moderate ED
Group III (n = 29) - severe ED
Group IV (n = 24) - EH
Group V (n = 48) - OSCC
NE NE Laminin-5 Tissue (F) Laminin-5 expression was sig-
nificantly increased in SCC, 
confirming its role as a marker 
of malignant transformation. 
The results of this study indicate 
that overexpression of laminin-5 
is found only in SCC and not 
dysplastic lesions.
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Anura et al. 
(2014) 
Group I (n = 20) - mild ED
Group II (n = 10) - moderate ED
Group III (n = 10) - severe ED
Group IV (n = 10) - NOM
Group V (n = 18) - OSFWT
OSFWT NE E-cad-
herin
Tissue (F) The positive correlation be-
tween deregulated expression 
of epithelial cell–cell adhesion 
molecule in oral submucous fi-
brosis with increase in dysplas-
tic grades suggested elucidatory 
potential of molecular expres-
sion features in assessment of 
malignant potentiality in oral 
submucous fibrosis.
de Freitas Silva 
et al. (2014)  
Group I (n = 10) - mild ED
Group II (n = 10) - moderate ED
Group III (n = 10) - severe ED
Group IV (n = 10) - NOM




Tissue (F) Significant differences in Twist 
and E-cadherin immunoexpres-
sion were observed between 
NOM and EDs, with an inverse 
relation since the earliest stages 
of oral dysplasia (r = 0,512; P 
< 0.001). The results showed a 
possible value of Twist and E-
cadherin in the prediction of 




Group I (n = 12) - Hyperkerato-
sis/mild ED
Group II (n = 7) - moderate ED
Group III (n = 6) - severe ED
Group IV (n = 25) - NOM











Tissue (F) The altered expression of 
Desmogleing3/γ-catenin and 
E-cadherin/β-catenin, in ODs/
OSCC imply their involvement 
in growth regulation and phe-
notype of dysplastic/malignant 
oral epithelial cells, contributing 
to the better understanding of 
epithelial dysplasia and OSCCs.
Von Zeidler et 
al. (2014) 
Group I (n = 23) - WD / mild ED
Group II (n = 8) - moderate/se-
vere ED





Tissue (F) Reduced E-cadherin expres-
sion was an early phenomenon 
observed in moderate-severe 
dysplasia, showing that the loss 
of epithelial cohesion may be an 
indicator of progression to oral 
cavity squamous cell carcinoma. 
Reyes et al. 
(2015) 
Group I (n = 21) - mild ED
Group II (n = 12) - moderate ED
Group III (n = 3) - severe ED
Group IV (n = 3) –NOM











β-catenin Tissue (F) Nuclear expression of β-catenin 
was observed in all samples with 
severe and moderate dyspla-
sia, with a median of 267.5, in 
comparison to mild ED whose 
median was 103.75. This finding 
suggests a role for β-catenin in 
the progression of ED and early 
malignant transformation to 
OSCC. 
Silva et al. 
(2015)
Group I (n = 19) - mild ED
Group II (n = 13) - moderate ED
Group III (n = 7) - severe ED






β-catenin Tissue (F) Cytoplasmic expression of 
β-catenin may represent the ini-
tial stage of modifications in the 
E-cadherin-catenin complex, 
along with changes in cell mor-
phology. 
Yagyuu et al. 
(2015) 
Group I (n = 58) - WD / mild ED
Group II (n = 36) - moderate/







Tissue (F) Cytokeratin-13 loss was found 
to be an independent diagnostic 
marker for high-grade dysplasia. 
Cytokeratin-13 loss may be use-
ful for distinguishing EDs from 
reactive atypical epithelium. 
Table 1 cont.: Summary of the descriptive characteristics and results of the included studies (n=17).
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Chandolia et 
al. (2017) 
Group I (n = 20) - mild ED
Group II (n = 20) - moderate ED
Group III (n = 20) - severe ED
Group IV (n = 10) - NOM
Group V (n = 30) – OSCC
NE NE N-Cadhe-
rin
Tissue (F) N-cadherin expression was 
more evident in OSCC than in 
oral ED. 
Gupta et al. 
(2018) 
Group I (n = 7) - mild ED
Group II (n = 7) - moderate ED
Group III (n = 7) - severe ED/
CIS
Group IV (n = 21) - OSCC
NE NE E-cadhe-
rin
Tissue (F) Loss of membranar E-cadherin 
expression and decrease in 
staining intensity were noted 
from ED to OSCC. 
Sharada et al. 
(2018) 
Group I (n = 10) - mild ED
Group II (n = 10) - moderate ED 
Group III (n = 10) - severe ED
Group IV (n = 10) -   OSFWT 
Group V (n = 10) - NOM
Group VI (n = 10) - OSCC
OSFWT NE E-cadhe-
rin 
Tissue (F) E-cadherin expression was 
membranar and continuous in 
all epithelial layers of NOM and 
reduced with progressing grades 
of oral ED to OSCC. 
Abbreviators: ♀, female; ♂, male; NOM, normal oral mucosa; OSFWT, oral submucous fibrosis without dysplasia; ED, Epithelial dysplasia; 
NE, Not specified; EH, Epithelial Hyperplasia; F, Formalin-fixed paraffin-embedded blocks; WD, without dysplasia; CIS, Carcinoma In Situ; 
OSCC, Oral Squamous Cell Carcinoma.
Table 1 cont.: Summary of the descriptive characteristics and results of the included studies (n=17).
The following EMT markers were analyzed accord-
ing to the criteria proposed by Zeisberg & Neil-
son8: β-catenin (18,19,26,28,29), γ-catenin (19,26), 
claudin-1 (20), E-cadherin (5,21,26,27,32,33), Twist 
(5,23), p-Akt (23), podoplanin (22), laminin-5 (24), 
desmoglein-3 (26), cytokeratin 13 and cytokeratin 
17 (30), and N-cadherin (31). The methods used for 
immunohistochemical analysis in the different stud-
ies selected were identified in this systematic review 
(Table 2).




Ishida et al. 
(2007) 
β-catenin For counting cells with nuclear and/or cytoplasmic staining, three microscopic fields (x200) were ran-
domly chosen and the mean above 10% of the total cell numbers was deduced to be positive. Evaluation 
of staining was carried out based on whether nuclear or cytoplasmic staining was detectable. Under mi-
croscopic fields (x200), tissues were considered positive for β-catenin if more than 10% of cells showed 






β-catenin and γ-catenin immunoexpression was quantitatively assessed as a percentage of the final 
number of 300 cells for each case. Cellular localization of immunolabelling was also classified as mem-




Claudin-1 Staining distribution was classified into focal (up to 30% of the epithelium) and diffuse (>30% of the 
epithelium). Epithelial localization, i.e., the predominant site of immunoexpression in epithelium, was 
divided into upper, middle, and lower third. Cellular localization, corresponding to the site of expres-
sion in the cell, was classified as membranar or membranar/cytoplasmic staining. Staining intensity was 
evaluated subjectively on a qualitative scale and was defined as weak, moderate or strong.






Immunoreactivity for E-cadherin, β-catenin, and APC was assessed using a semiquantitative method 
based on the proportion of positive cells and staining intensity: Immunoreactivity score = proportion 
positive score x intensity score. The proportion of positive staining was scored as follows: 0 (0–20% of 
epithelial cells stained positive), 1 (21–40% of positive cells), 2 (41–60% of positive cells), 3 (61– 80% of 
positive cells), or 4 (>80% of positive cells). The intensity was scored as: 0 (negative staining), 1 (weak 
intensity), 2 (moderate intensity), or 3 (strong intensity). Immunoreactivity for vimentin was assessed us-
ing the Label Index (Li) score, which presents the proportion of positively-stained cells as a percentage.
Inoue et al. 
(2012) 
Podoplanin The intensity of immunoexpression was scored as follows: 0 (no expression in any part of the epithelium); 
1 (intensity weaker than that in lymphatic vessels as a positive control, and expression observed in the 
basal layer; 2 (intensity weaker than that in lymphatic vessels, and expression was observed in more than 
two layers; 3 (intensity equal to that in lymphatic vessels, and expression observed in basal layer); and 
4 (intensity equal to that in lymphatic vessels, and expression observed in more than 2 layers. The score 
was based on examination of the whole section.




Five histological fields were randomly chosen, and 1000 cells were counted in each slide. The analysis 
was performed by counting positive cells in cytoplasmic and/or nuclear compartments.
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Rani et al. 
(2013) 
Laminin-5 The extent of positive immunostaining was calculated by subtracting the negative control strongly posi-
tive cytoplasmic or nuclear pixel count from the matching area with a strongly positive cytoplasmic or 
nuclear pixel count on the study slides. This resultant normalized positive immunohistochemistry pixel 
count was divided by the area (square millimeters) to provide a comparable indicator of immunopositiv-
ity among individual tissue samples.
Anura et 
al. (2014) 
E-cadherin The epithelium was demarcated into proliferative and differentiative layers to evaluate the differential 
expression pattern of the molecules using intensity scores. To evaluate E-cadherin expression, random 
points corresponding to each layer were selected from randomly selected microphotographs of the stud-
ied groups. Expression intensity scores were given to each point in the range of ‘0–10’, where: ‘10-8’ 
(intensely deep color), ‘7-6’ (deep color), ‘5-3’ (faint) and ‘2-0’ (very faint color). The intensity of E-
cadherin expression in cell membrane and cytoplasm was scored separately.
de Freitas 




The analysis of Twist immunoexpression was performed taking in count the percentage of positive stain-
ing cells in the whole examined area. For Twist evaluation, the percentage of positive cells was clas-
sified into four categories: 1 (<25%); 2 (25%-50%); 3 (51%-75%); 4 (>75%). For E-cadherin, immuno-
histochemical staining was evaluated as: 1 (less than 25% positive cells); 2 (heterogeneous staining in 
25%-50% of cells); 3 (homogenous staining in 50%–75% of cells); 4 (strong staining in more than 75% 
of cells).
Kyrodimou 





Immunoreactivity of the examined biomarkers was semiquantitatively assessed and positive staining 
was characterized as membranar, cytoplasmic, or nuclear. The scoring grading was based on the percent-
age of positive cells. Immunostaining was considered positive if greater than or equal to 5% of tumour 
cells were stained and the scoring was graded in a I-III scale according to the percentage of positive cells: 
I (6-35%), II (36–70%), and III (71–100%).
Von Zei-
dler et al. 
(2014) 
E-cadherin The analysis of E-cadherin immunoexpression was performed by calculating the percentage of posi-
tive staining cells in relation to the whole examined area. A semiquantitative scoring system was used, 
based on the staining pattern on a four-point scale: 0 (negative, with absent or discontinued membranar 
staining); 1 (weak; 1-50% of cells stained); 2 (moderate; 51-75% of cells stained); and 3 (strong; >75% of 
cells stained. A total index score was obtained by summing the results of all layers (basal, parabasal and 
keratinized) in the groups with normal oral mucosa and  epithelial dysplasia; tumor front was analyzed 
at oral squamous cell carcinoma.
Reyes et al. 
(2015) 
β-catenin The cellular localization of β-catenin was classified as membranar, cytoplasmic or nuclear, depending 
on the immunolocalization pattern. Intensity of membranar staining was assessed as mild, moderate 
or intense. Five randomly selected fields with presence of dysplastic and/or neoplastic epithelium were 
assessed. In these photomicrographs, 1000 epithelial cells were counted per case and the number of posi-
tive cells was determined with the Image J software.
Silva et al. 
(2015) 
β-catenin A qualitative β-catenin analysis was performed based on the percentage of positive cells, considering as 
positive only specimens with 25% or more cells presenting β-catenin expression. The cellular localiza-
tion (membranar, cytoplasmic and nuclear) and the epithelial layer (basal, parabasal, and spinous cell 
layers) were also considered. β-catenin immunoexpression was analyzed by two independent blind and 





CK13 was scored as follows: 0, strong and diffuse expression; 1, weak and/or patchy expression; or 2, no 
expression. CK17 was scored as follows: 0, no expression; 1, weak and/or patchy expression; or 2, strong 
and diffuse expression. Discrepant slides were re-evaluated using a dual vision microscope to achieve 
a consensus.
Chando-
lia et al. 
(2017) 
N-Cadherin Brownish staining in cell membrane and cytoplasm was considered as positive staining. The expression 
was classified based on the intensity of staining and the percentage of cells exhibiting membranar stain-
ing. The sections were observed at low magnification to identify positively stained areas (hot spots). In 
the control and dysplasia groups, the positivity of N-cadherin expression was analyzed in epithelium in 
basal and spinous layer. Based on the total score, the final expression was graded as negligible (0-2), mild 
(3-5), moderate (6-8), or intense (9-12).
Gupta et al. 
(2018) 
E-cadherin Intensity of staining: 0 = absent/loss of expression; 1 = weak/light staining; 2 = moderate staining; 3 
= strong/intense staining. Membranar staining expression: 0 = 0 to 10% of cells showing a complete 
membranar staining; 1 = 11 to 50% of cells showing a complete membranar staining; 2 = 51 to 75% of 




E-cadherin Cells showing membranar staining were considered positive for E-cadherin. The intensity of immuno-
expression was assessed and scores were interpreted as follows: 0 (no positive cells); 1+ (mild intensity); 
2+ (moderate intensity); 3+ (strong intensity). The obtained score was tabulated as quick score (QS). The 
QS was calculated for basal cells, parabasal cells, superficial cells (including intermediate cells) and 
corneal cells in all six groups and for epithelial cells in the connective tissue stroma of oral squamous 
cell carcinoma.
Table 2 cont.: Immunohistochemical analysis used in the selected studies.
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- Quality assessment and Risk of bias
We used the criteria established by the REMARK 
guidelines to evaluate the studies included in the sys-
tematic review (Table 3). The selected studies provid-
ed details about the objective/hypothesis of the study, 
characteristics of the patients included in the sample, 
analysis method used, and relationship of the EMT 
markers with the degree of epithelial dysplasia in the 
cases analyzed. In addition, the studies discussed impli-
cations for future studies and clinical value.
Based on the MAStARI assessment, 2 articles (18,32) 
were classified as carrying a high risk of bias, mainly 
because the answers for questions 3 and 4 (related to co 
-founding factors, description of the groups and follow-up, 
respectively) were “No”. Fifteen studies were classified 
as with low risk for bias (5,19-22,25,26-31,33) (Table 4).
Checklist Criteria
Introduction The hypotheses and objectives of the study were clearly explained.
Cohort description Retrospective or prospective cohort with a well-defined study population.
Medical treatment of the cases was explained.
Patient data The basic data such as age, gender, clinical stage and histopathologic grade was provided.
Evaluation method Well-described method including the microscopic field/s and the cutoff point. Inter-observer 
variability was evaluated.
Prognostic analysis The survival end point was defined and/or the relationship between the tumour budding and 
lymph node metastasis was studied.
Statistical analysis Estimated effect (e.g., hazard ratio, relative risk with their confidence interval), which reveal 
the relationship between tumour budding and the survival end point/s
The independence of prognostic value was reported by multivariate analysis
Classical prognostic factors The prognostic value of the classical prognostic factors (e.g., stage and grade) were reported.
The relationship between tumour budding and classical prognostic factors was reported.
Interpretation of the prognos-
tic value and discussion
Comparison of the current findings with other studies.
Strengths and limitations of the current data.
Recommendation for further research.
Author (year) Questions* % Yes # Risk of 
BiasQ1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
Ishida et al. (2007) NA Y N Y N N NA Y Y 57.1 H
Lo Muzio et al. (2009) NA Y N Y Y N NA Y Y 71.4 L
Carvalho et al. (2010) NA Y Y Y Y N NA Y Y 85.7 L
Chaw et al. (2012) NA Y Y Y Y N NA Y Y 85.7 L
Inoue et al. (2012) NA Y Y Y N N NA Y Y 71.4 L
Silva et al. (2012) NA Y Y Y Y N NA Y Y 85.7 L
Rani et al. (2013) NA Y Y Y N N NA Y Y 71.4 L
Anura et al. (2014) NA Y N Y Y N NA Y Y 71.4 L
de Freitas Silva et al. (2014) NA Y Y Y Y N NA Y Y 85.7 L
Kyrodimou et al. (2014) NA Y Y Y N N NA Y Y 71.4 L
Von Zeidler et al. (2014) NA Y Y Y N N NA Y Y 71.4 L
Reyes et al. (2015) NA Y N Y Y N NA Y Y 71.4 L
Silva et al. (2015) NA Y Y Y Y N NA Y Y 85.7 L
Yagyuu et al. (2015) NA Y Y Y Y N NA Y Y 85.7 L
Chandolia et al. (2017) NA Y Y Y Y N NA Y Y 85.7 L
Gupta et al. (2018) NA Y N Y N N NA Y Y 57.1 H
Sharada et al. (2018) NA Y Y Y N N NA Y Y 71.4 L
Q1. Is the study based on a random or pseudorandom sample?
Q2. Are the criteria for inclusion in the sample clearly defined?
Q3. Are confounding factors identified and strategies to deal with them stated?
Q4. Are outcomes assessed using objective criteria?
Q5. If comparisons are being made, was there sufficient description of the groups?
Q6. Is follow up carried out over a sufficient time period?
Q7. Are the outcomes of people who withdrew described and included in the analysis?
Q8. Are outcomes measured in a reliable way?
Q9. Is appropriate statistical analysis used?
*Y=Yes, N=No, NA=Not applicable (which was not considered on the percentage calculation)
# Risk of bias was categorized as high (H) when the study reaches up to 49% score “yes”, moderate (M) when the study reached 50% to 69% score
“yes”, and low (L) when the study reached more than 70% score “yes”.
Table 3: Evaluation criteria used to assess the quality of studies evaluated (adapted from REMARK guidelines).
Table 4: Analysis of the risk of bias of the articles included in the review was performed with the MAStARI (Meta-Analysis of Statistics As-
sessment and Review Instrument) critical appraisal tool.
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- Cell-surface and cytoskeletal markers of the epitheli-
al-mesenchymal transition
Among the 17 selected studies, 15 evaluated cell sur-
face and/or cytoskeletal markers (5,18-22,25-33). These 
studies demonstrated significant dysregulation of the 
expression of the proteins analyzed according to the de-
gree of dysplasia.
In our systematic review, β-catenin was a biomarker 
strongly associated with the progression of oral epithe-
lial dysplasia. Ishida et al. (18) detected strong immu-
noexpression of β-catenin in the cell nucleus of cases 
diagnosed as oral epithelial dysplasia, with a significant 
difference between dysplasia samples and normal oral 
epithelium (P < 0.01) and between oral leukoplakia 
with dysplasia and the group without dysplastic altera-
tions (P < 0.01). Lo Muzio et al. (19) observed the loss 
of membrane expression of β- and γ-catenin with in-
creasing degree of oral epithelial dysplasia and a shift 
of expression to the cytoplasm. The same finding was 
reported in the other studies included (21,29).
The loss of membrane expression of cell adhesion 
markers and the translocation of immunopositivity to 
the cytoplasm was a common finding and was strongly 
associated with an increase in the degree of oral epithe-
lial dysplasia. Carvalho et al. (20) demonstrated that all 
cases of mild epithelial dysplasia and 73.1% of cases of 
moderate epithelial dysplasia exhibited only membrane 
immunopositivity, while membrane/cytoplasmic stain-
ing was observed in cases of severe epithelial dyspla-
sia. These findings show the dysregulation of protein 
expression with increasing degree of dysplasia.
Chaw et al. (21) observed a significant correlation be-
tween the loss of E-cadherin expression and increased 
vimentin expression in the cytoplasm in moderate/se-
vere epithelial dysplasias. The expression of vimentin 
was also positively correlated with the cytoplasmic and 
nuclear expression of β-catenin (r = 0.467, P < 0.05). De 
Freitas Silva et al. (5) demonstrated a gradual loss of E-
cadherin expression with increasing degree of dysplasia 
of the oral epithelium.
- Extracellular proteins and transcription factors
Although recognized as important markers associ-
ated with the EMT process, studies analyzing the role 
of transcription factors and extracellular proteins in 
oral epithelial dysplasia by immunohistochemistry are 
scarce. Silva et al. (23) reported a significant variation 
in the Twist transcription factor among five groups ana-
lyzed. The authors observed higher immunopositivity 
in cases of severe epithelial dysplasia compared to mod-
erate dysplasia (P = 0.047) and a progressive increase of 
expression in cases of OSCC compared to severe epithe-
lial dysplasia (P = 0.007).
In the study of De Freitas Silva et al. (5) immunostain-
ing for the Twist protein was mainly observed in the 
parabasal and basal layers of the normal oral epithelium 
and in the groups with mild and moderate dysplasia, ex-
hibiting a predominant cytoplasmic localization. How-
ever, in cases of severe epithelial dysplasia, immunoex-
pression was also detected in the superficial layers of 
the epithelium, indicating dysregulation of protein ex-
pression in advanced stages of epithelial dysplasia. The 
authors also showed a statistically significant correla-
tion in the immunoexpression of Twist and E-cadherin, 
with the observation of an inverse relationship between 
the immunoexpression of these proteins (r = 0.512; P < 
0.001).
Rani et al. (24) observed low expression of laminin-5 
in cases of epithelial dysplasia, with predominantly 
weak and cytoplasmic immunostaining. In that study, 
the expression of laminin-5 did not differ significantly 
according to the degree of dysplasia. A significant in-
crease in laminin-5 immunopositivity was only found 
in cases of OSCC compared to the epithelial dysplasia 
groups, suggesting a role of this protein in the invasion 
of the already established neoplastic process.
Discussion
The present study analyzed the role of EMT in cases 
diagnosed with oral epithelial dysplasia. The malignant 
transformation of OPMDs is an important process in 
oral carcinogenesis, which is still poorly understood. 
Thus, the identification of markers that are associated 
with the development and progression of oral epithelial 
dysplasia is of paramount importance for establishing a 
possible relationship with the prognosis of these lesions. 
The histopathological classification of oral epithelial 
dysplasia can assist in the monitoring and definition of 
the most appropriate treatment; however, other factors 
may be determinant in the process of malignant trans-
formation (34,35).
Several biomarkers are being analyzed by immunohis-
tochemistry in order to evaluate their participation in 
oral epithelial dysplasia (3,6). In clinicopathological 
practice, immunohistochemistry is relatively easy to 
apply and more accessible than other techniques.
The EMT has been indicated as an important process 
in carcinogenesis that is directly associated with the ag-
gressiveness of OSCC. During this process, epithelial 
cells lose their capacity of cell-cell adhesion. In addi-
tion, reorganization of the cytoskeleton and significant 
changes in signaling occur that define the shape and 
structure of the neoplastic cell. EMT is believed to be 
the result of reprogramming of gene expression medi-
ated by transcription factors such as Twist, Snail, and 
Slug (10,36-38). This transition increases cell motility 
and enables the development of an invasive phenotype 
(37). Despite advances in the understanding of the func-
tion of EMT in already established OSCC, it is neces-
sary to identify the role of EMT markers in the develop-
ment and progression of oral epithelial dysplasia.
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The loss of cell adhesion is likely to play a key role in 
EMT. This phenomenon can be observed in our system-
atic review by the loss of membrane expression of cell 
adhesion markers such as claudin-1 and, particularly, 
E-cadherin in cases diagnosed as epithelial dysplasia 
(5,10,21,26,27,32,33,36,38). Furthermore, E-cadherin 
was immunoexpressed in the cytoplasm of epithelial 
dysplasia cases. In this respect, studies have shown that 
the cytoplasmic expression of this protein is frequently 
associated with tumors in advanced stages (39,40). It is 
possible that the loss of membrane expression and the 
onset of E-cadherin translocation to the cytoplasm, and 
consequently the loss of basic functions associated with 
cell adhesion, occur during the early stages of oral car-
cinogenesis and are already present in cases of oral epi-
thelial dysplasia, progressing with increasing severity 
of the latter.
Twist is an important nuclear transcription factor for 
EMT. De Freitas Silva et al. (5) indicated a repressive 
effect of Twist on the expression of E-cadherin in epi-
thelial dysplasia and oral cancer. Furthermore, previous 
studies have elucidated the role of Twist in the already 
established neoplastic process, which negatively regu-
lates the expression of E-cadherin and the overexpres-
sion of mesenchymal markers (5,10,37). Other transcrip-
tion factors with a potential role in the development and 
progression of oral epithelial dysplasia need to be better 
investigated. Zheng et al. (41) reported the overexpres-
sion of the transcription factors Snail and Slug to be 
associated with a poor prognosis of the neoplastic pro-
cess. The Twist, Snail and Slug proteins seem to a play a 
similar role in the repression of E-cadherin and, appar-
ently, the expression of these proteins is also related to 
the regulation of β-catenin (42).
The binding of E-cadherin to β-catenin in the cyto-
plasm/membrane represses tumor progression, main-
taining cell-cell adhesion and inhibiting EMT, cell mo-
tility and tumor metastasis (42). The negative regulation 
or loss of E-cadherin and β-catenin expression, as well 
as the immunoexpression of β-catenin in the nucleus, is 
frequently observed in several type of cancer, including 
head and neck cancer. In our systematic review, the nu-
clear expression of β-catenin was a frequent finding in 
the samples of cases diagnosed as advanced oral epithe-
lial dysplasia and might be an important marker associ-
ated with the progression of this condition (18,21,28).
Prgomet, Andersson, & Lindberg44 evaluated the ex-
pression of WNT5A, β-catenin and E-cadherin by im-
munohistochemistry in 21 tissue samples. Each sample 
contained areas of mucosa with normal appearance, 
oral epithelial dysplasia, and OSCC. In that study, mem-
brane expression of β-catenin was lower in OSCCs than 
in dysplasia or normal-appearing mucosa regions, while 
cytoplasmic expression of β-catenin increased with the 
severity of dysplasia and was detected in half of the 
OSCCs. Similar findings of reduced membrane expres-
sion of β-catenin and progression of oral carcinogenesis 
were reported in the studies included in our systematic 
review. The cytoplasmic accumulation and subsequent 
nuclear translocation of β-catenin might be the result 
of activation of the canonical Wnt signaling pathway or 
impairment of this pathway due to mutations in some 
of its components. The cytoplasmic/nuclear overexpres-
sion of β-catenin is known to be associated with malig-
nant transformation in different types of cancer (28,45).
Recent in vitro studies confirm the role of EMT mark-
ers in the progression of oral epithelial dysplasia. Dm-
ello et al. (46) evaluated the expression of vimentin in 
epithelial cells derived from OPMDs. In that study, the 
exogenous expression of vimentin contributed to the oc-
currence of EMT and subsequent malignant transforma-
tion. Epigenetic markers may regulate EMT. Members 
of the miR-200 family have been shown to be negatively 
regulated in human cancer cell lines and play a critical 
role in the suppression of EMT, tumor cell adhesion, 
migration, invasion, and metastasis (47). Arunkumar et 
al. (48) demonstrated expressive negative regulation of 
miR-200 in poorly differentiated OSCC by RT-qPCR 
analysis (P = 0.0067). However, there are no studies in-
vestigating epigenetic markers associated with EMT in 
oral epithelial dysplasia.
Conclusions
In conclusion, the dysregulation of expression of EMT-
associated proteins in dysplastic oral epithelium is a po-
tential prognostic marker. The results showed a progres-
sive increase in the expression of nuclear transcription 
factors and markers of mesenchymal differentiation, as 
well as negative regulation of epithelial and cell adhe-
sion markers, according to the severity of oral epithelial 
dysplasia. It should be noted that the studies included 
in this systematic review examined OPMDs that were 
not continuously followed up from the time of diagnosis 
to malignant transformation. Longitudinal studies are 
necessary to identify the possible association of EMT 
with the risk of malignant transformation of OPMDs.
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